X4 Pharmaceuticals, Inc. (XFOR)
2.81
+0.04
(+1.44%)
USD |
NASDAQ |
Oct 07, 11:51
X4 Pharmaceuticals Net Income (Quarterly) : -16.16M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -16.16M |
| March 31, 2026 | -20.24M |
| December 31, 2025 | -23.92M |
| September 30, 2025 | -29.82M |
| June 30, 2025 | -25.74M |
| March 31, 2025 | 0.282M |
| December 31, 2024 | -39.82M |
| September 30, 2024 | -36.70M |
| June 30, 2024 | 90.83M |
| March 31, 2024 | -51.77M |
| December 31, 2023 | -19.13M |
| September 30, 2023 | -2.305M |
| June 30, 2023 | -55.71M |
| March 31, 2023 | -24.02M |
| December 31, 2022 | -29.10M |
| September 30, 2022 | -21.59M |
| June 30, 2022 | -21.21M |
| March 31, 2022 | -21.96M |
| December 31, 2021 | -30.21M |
| September 30, 2021 | -20.18M |
| June 30, 2021 | -19.64M |
| Date | Value |
|---|---|
| March 31, 2021 | -18.68M |
| December 31, 2020 | -18.40M |
| September 30, 2020 | -17.45M |
| June 30, 2020 | -15.14M |
| March 31, 2020 | -11.14M |
| December 31, 2019 | -10.84M |
| September 30, 2019 | -17.71M |
| June 30, 2019 | -13.38M |
| March 31, 2019 | -10.87M |
| December 31, 2018 | -11.28M |
| September 30, 2018 | -8.602M |
| June 30, 2018 | -6.034M |
| March 31, 2018 | -7.367M |
| December 31, 2017 | -11.19M |
| September 30, 2017 | -11.60M |
| June 30, 2017 | -5.705M |
| March 31, 2017 | -5.385M |
| December 31, 2016 | -5.321M |
| September 30, 2016 | -8.994M |
| June 30, 2016 | -5.16M |
| March 31, 2016 | -3.50M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Sarepta Therapeutics, Inc. | -4.89M |
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
| Sangamo Therapeutics, Inc. | -31.00M |
| Anixa Biosciences, Inc. | -2.625M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 8.806M |
| Total Expenses (Quarterly) | 24.96M |
| EPS Diluted (Quarterly) | -0.1279 |
| Enterprise Value | 134.91M |
| Gross Profit Margin (Quarterly) | 81.24% |
| Profit Margin (Quarterly) | -183.5% |
| Earnings Yield | -42.48% |
| Normalized Earnings Yield | -42.20 |